Search

In a world where one in every two people will be diagnosed with cancer in their lifetime, the Publicis Foundation is launching the first cross-industry coalition to erase the stigma of cancer in the workplace, supported by leading cancer charities and organizations including Memorial Sloan Kettering Cancer Center (MSK), MacMillan Cancer Support and the Gustave Roussy Institute.

An MSK study explains how the drug selinexor, which was recently approved to treat multiple myeloma and is being tested in many other tumor types, stops cancer.

More than 20 years ago, this SKI scientist laid the groundwork for a field that is now transforming medicine.

Learn how MSK helps people facing cancer in every way they need, and understands the importance of speaking to patients in the language that provides them peace of mind.

Descubra cómo MSK ayuda a las personas que se enfrentan al cáncer en todo lo que necesitan, y comprende la importancia de hablar con los pacientes en el idioma que les brinda tranquilidad.

A team at MSK uncovered how TRX518, a new immunotherapy drug in early development, works in the body.

Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of its new Teen and Young Adult (TYA) Program, TYA  @  MSK, which will offer special services to MSK’s TYA population. In tandem, MSK officially opened The Lounge, a space designed especially for this unique age group that was made possible by a $1 million donation from Teen Cancer America. The nonprofit organization, co-founded by Roger Daltrey and Pete Townshend of The Who, partners with hospitals throughout the United States to develop specialized facilities for teens and young adults with cancer.

Patients with advanced kidney cancer can now take advantage of a new treatment option that has far fewer troubling side effects – this, according to a large, international trial led by Memorial Sloan Kettering Cancer Center investigators.